INTRODUCTION
, first reported the use of gastric segments for bladder reconstruction in an animal model. [1] It was not used regularly in pediatric patients until 1988 when Adams et al. published their experience as an alternative use of intestine for bladder reconstruction. [2] Initially, it
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For reprints contact: reprints@medknow.com was used for patients with renal insufficiency, acidosis, or short bowel syndrome, but later, neurogenic cases were also benefitted from this procedure. However, recognition of complications prompted a reduction of its use at many centers, and gastrocystoplasty was kept as an alternative to ileal or sigmoid bladder reconstruction only in a minority of selected cases. In this study, we have reviewed our experience with gastrocystoplasty in a tertiary pediatric referral center and tried to assess the effect of gastrocystoplasty on height and bone density in children who underwent gastrocystoplasty because of various reasons.
AIM AND OBJECTIVE
To analyze the long-ter m outcome following gastrocystoplasty in terms of height, bone mineral density, acid base changes, and complications.
MATERIALS AND METHODS
This study is a cross-sectional study done after obtaining institutional ethics committee clearance. pre-augmentation and post-augmentation renal, biochemical, and ABG parameters are shown in Table 3 . Bone density values were available in 16 patients post-augmentation.
The mean value post-augmentation gastrocystoplasty was 0.654 [ Table 4 ]. The overall rate of complication in our study group was 26%, the most common being Hematuria-dysuria syndrome seen in 13% [ Table 5 ]. Four percent of our cases developed vesical calculi and 8% developed febrile UTI six months post-augmentation. None of our patients developed severe hypochloremic metabolic alkalosis.
DISCUSSION
Over the decades, the use of gastric tissue for lower urinary tract reconstruction has decreased significantly. Most pediatric cases were done mainly in the 1990s. Initial indications included patients with renal insufficiency and short bowel syndrome, but later indications also expanded to patients with neurogenic bladder and others. [5] [6] [7] [8] Benefits of the use of stomach included decreased mucous production, avoidance of hyperchloremic metabolic acidosis, and decreased rate of bladder stone formation. Other anatomical advantages were availability and the possibility of performing cystoplasty without detubularization. In addition, the gastric wall thickness allowed ureteral reimplantation or reimplantation of catheterizable channels when necessary. Likewise, gastric tissue has been combined with other intestinal segments as a composite urinary reservoir to decrease the disadvantages of each individual segment. The augmentation procedure is carried out to reduce the intravesical pressure, to preserve the upper tracts, and to improve the continence reservoir function of the bladder and hence the quality of life. The association between enterocystoplasty and a reduction in the growth and development was noticed in 1992 by Wagstaff et al., but this was a retrospective study and had unclear definition of growth rate; hence, the results remained provocative yet unsubstantiated. [9] Although Wagstaff initially reported growth failure in 12 patients, subsequent follow up 10 years later had refuted the initial findings. In our study, we could not find decrease in the percentile heights or weight of children post-augmentation when compared with pre-augmentation values. There was no decrease in the linear growth as well. Mingin et al. had reported no change in linear growth among 33 augmented children, a finding in concordance with our study. [10] Only few studies are available regarding the bone mineral density in augmented children. Mingin et al. and Kockum et al. reported no significant change in bone mineral density in exstrophy bladder cases after a follow up period of 3.7 years.
[11] Ugur Boylu et al. have evaluated bone mineral density in children with and without myelomeningocele and concluded that after augmentation, the bone mineral density was lower in cases of myelomeningocele, may be because of underlying neurologic pathology and its locomotor consequences. [12] In our study group, results of 16 post-augmented children were compared with normal Indian children and exstrophy patients who were not augmented, and we found no significant difference among the groups. Mucous production and bladder stone formation are both complications related to the use of bowel for urinary reconstructions. In our study group, the incidence of stone formation was found to be 4%, which was comparable to other studies. [3, 4] In our study, none of the 23 patients had bothersome mucus production and none needed routine bladder drainage. Our policy is to keep all patients under routine chemoprophylaxis for 6 months. Two (8%) of our patient had febrile UTI 6 months after augmentation. In our study group, hematuria-dysuria syndrome which was first described by Nhuyen et al. and broadly defined as one or a combination of bladder spasm, suprapubic, penile or periurethral pain, coffee brown or bright red hematuria without infection, skin irritation or excoriation was seen in 3 (13%) patients. [13] All three cases were managed on an outpatient basis with oral sodium bicarbonate and proton pump inhibitors, and none of them required hospitalization. None of our patient developed severe hypochloremic metabolic alkalosis.
CONCLUSION
Hence, we can conclude from our study that augmentation gastrocystoplasty is a safe and viable option without any adverse effect on height or bone mineral density without significantly altering metabolic or acid base homeostasis.
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